Brandywine Managers’s Structure Therapeutics GPCR Stock Holding History

Brandywine Managers’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$717K	Hold	13,357	–	–	0.35%	28
2026 Q1	$644K	Hold	13,357	–	–	0.38%	22
2025 Q4	$929K	Buy	13,357 +2,300	+21%	+$93.9K	0.46%	20
2025 Q3	$310K	Hold	11,057	–	–	0.3%	32
2025 Q2	$229K	Hold	11,057	–	–	0.23%	31
2025 Q1	$191K	Hold	11,057	–	–	0.23%	32
2024 Q4	$300K	Hold	11,057	–	–	0.32%	31
2024 Q3	$485K	Hold	11,057	–	–	0.52%	27
2024 Q2	$434K	Sell	11,057 -950	-8%	-$39K	0.46%	27
2024 Q1	$515K	Hold	12,007	–	–	0.51%	26
2023 Q4	$489K	Buy	12,007 +1,007	+9%	+$57.7K	0.54%	29
2023 Q3	$555K	Buy	+11,000	New	+$354K	0.94%	23

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Brandywine Managers's GPCR Position: Q2 2026 in Review

Brandywine Managers held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 13,357 shares worth $717K. The position accounts for 0.35% of the portfolio, ranked #28.

Brandywine Managers first reported a position in GPCR in Q3 2023 and has held it in 12 quarters since. The position peaked at $929K in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Brandywine Managers held 13,357 shares of Structure Therapeutics worth $717K as of Q2 2026.
Brandywine Managers left its Structure Therapeutics share count unchanged in Q2 2026.
Structure Therapeutics made up 0.35% of Brandywine Managers's portfolio in Q2 2026, its #28 holding.
Brandywine Managers first reported a position in Structure Therapeutics in Q3 2023 and has held it in 12 quarters since.
Brandywine Managers's Structure Therapeutics position peaked at $929K in Q4 2025.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Brandywine Managers's 13F filing for Q2 2026, filed 14 Aug 2026.